SCHEMBL1958747

SCHEMBL1958747

COC(=O)c1cnc2c(c1)cc(C(=O)CC1CCCC1)n2S(=O)(=O)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
KMT2A Q03164 2/20 0.38
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
CCND3 P30281 1/20 0.36
CDK6 Q00534 1/20 0.36
KDM4E B2RXH2 2/20 0.36
HSD17B10 Q99714 1/20 0.36
NAMPT P43490 3/20 0.36
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35
BCHE P06276 2/20 0.35
HTR6 P50406 2/20 0.35
CYP19A1 P11511 1/20 0.35
PSMD14 O00487 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1958748 0.87 FKBP1A (0.38) KMT2ALMNASMN1; SMN2HTR6RAB9A
SCHEMBL1960226 0.86 FKBP1A (0.38) ALDH1A1KMT2AKDM4ELMNASMN1; SMN2
SCHEMBL1962993 0.86 PDE5A (0.38) ALDH1A1KMT2AKDM4ELMNA
SCHEMBL1959207 0.85 AADAT (0.36) ALDH1A1HSD17B10NAMPTLMNABCHE
SCHEMBL1959282 0.84 ALDH1A1 (0.36) ALDH1A1CDK4CCND1LMNABCHE
SCHEMBL1961745 0.83 NAMPT (0.37) ALDH1A1KMT2AKDM4ENAMPTLMNA
SCHEMBL1959421 0.83 KDM4E (0.36) ALDH1A1KMT2AKDM4EHSD17B10NAMPT
SCHEMBL1963672 0.82 PTGDR (0.34) ALDH1A1HSD17B10LMNABCHEHTR6
SCHEMBL1962404 0.81 ALDH1A1 (0.41) ALDH1A1KMT2AKDM4ELMNA
SCHEMBL1959106 0.81 RORC (0.44) BCHEHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 ALDH1A1 769/4885KMT2A 1524/4885CDK4 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.